Drug Trial Radar · NCT05801094
A Phase I Study of QL1604 for Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
71
Actual
Start
Jul 20, 2020
Primary completion
Apr 15, 2023
Study completion Dec 15, 2023
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, patients with advance solid tumors will be treated with QL1604 monotherapy.
Conditions
- Advanced Solid Tumor
Interventions
QL1604Drug
QL1604 3 mg/kg Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: up to 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affliated Hospital of Nanchang University
Nanchang, China
Fudan University Shanghai Cancer Center
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.